Boston-based Verastem has launched its “Reimagine” campaign to encourage healthcare professionals (HCPs) and patients to ...

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...

As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...

The European Medicines Agency (EMA) has launched an advisory group designed to help boost “vaccine confidence” amid growing ...

The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s ...

Novartis will construct an active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, the company said ...

In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...

As regulatory delays continue to plague Regeneron’s efforts to develop Eylea, sales for the eye disease medicine remain in ...

Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have ...

Novartis CEO Vas Narasimhan says Europe needs a “complete rethink” of how it prices its drugs, warning that the entrance of ...

As Ekterly nears the one-year anniversary of its FDA approval, Italy’s Chiesi Group is making moves to acquire the rare ...